SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD
Purpose: To present Week (W) 24 results from the SPECTRUM study on the real-world effectiveness and safety of aflibercept 8 mg in patients with treatment-naïve (TN) and previously treated (PT) neovascular age-related macular degeneration (nAMD). Methods: SPECTRUM (NCT06075147) is an ongoing, [for full text, please go to the a.m. URL]
Authors
- Aude Ambresin (ORCID: https://orcid.org/0000-0002-6543-3400)
- Tobias Machewitz
- Paolo Lanzetta (ORCID: https://orcid.org/0000-0003-3746-141X)
- Hassiba Oubraham (ORCID: https://orcid.org/0000-0002-9004-6867)
- Sarah Schlief
- Susanne Oesch
- C. Lange
- Marion Munk
- Peter Morgan-Warren (ORCID: https://orcid.org/0000-0002-0597-6040)
- Andreas Stahl
- Vasileios Konidaris
- Clare Bailey
- Varun Chaudhary
- Martin Kirchner
Institutions
- CGIAR (FR)
- University of Udine (IT)
- University of Freiburg (DE)
- Universitätsmedizin Greifswald (DE)
- University Hospitals Bristol NHS Foundation Trust (GB)
- University Hospitals of Leicester NHS Trust (GB)
- Addiction Switzerland (CH)
- Bayer (Switzerland) (CH)
- Orthopädische Praxis (DE)
- Bayer (Germany) (DE)
- McMaster University (CA)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-17
- DOI
- https://doi.org/10.3205/26doc132
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00